Axsome Therapeutics, Inc.
One World Trade Center
29th Floor
New York, NY 10007
Tel: +1 212.332.3241
Fax: +1 212.320.0245
www.axsome.com

Submission Date: August 25, 2026

Simran Parihar, PharmD, RPh
Senior Regulatory Project Manager
Division of Regulatory Operations for Neuroscience
Division of Psychiatry

Food and Drug Administration
Center for Drug Evaluation and Research
10903 New Hampshire Avenue
Silver Spring, MD 20993

RESPONSE TO PREA NONCOMPLIANCE LETTER
DEFERRAL EXTENSION REQUESTED

Re: NDA No. 215430: Sequence No. 0423
Correspondence Regarding Post-Marketing Requirements 4233-1, 4233-2, and 4233-3

Dear Dr. Parihar,

Reference is made to New Drug Application (NDA) 215430 – AUVELITY (dextromethorphan HBr and bupropion HCl) extended-release tablets for the treatment of major depressive disorder (MDD), approved on August 18, 2022, and for the treatment of agitation associated with dementia due to Alzheimer's disease (AD agitation), approved on April 30, 20. Reference is also made to IND 124813 – AXS-05 (dextromethorphan-bupropion) for the treatment of MDD and treatment resistant depression (TRD), and to the Notification of Non-Compliance with PREA letters dated August 13, 2026 for Post-Marketing Requirements (PMRs) 4233-1 and 4233-2, and to the PMR Not Fulfilled letter dated September 8, 2026 for PMR 4233-1.

Please find our Response to these letters located in Module 1.17.2 of this serial submission, which includes the reason for the delayed pediatric assessments as well as the date by which we expect to submit them. Included in this Response is a Deferral Extension Request, proposing new milestone dates for PMRs 4233-1, 4233-2, and 4233-3.

Please do not hesitate to contact me if you have any questions.

Sincerely,
Daniel Bigelow
Digitally signed by Daniel Bigelow
Date: 2026.09.25 18:31:00 -04'00'

Daniel Bigelow
Executive Director, Regulatory Affairs
AXSOME Therapeutics, Inc.
Tel. +1 (917) 716-2299
dbigelow@axsome.com

This submission is being submitted electronically, in eCTD format, via the FDA ESG. Malwarebytes, with the most recently available malware definitions was used to ensure the files are free from known threats.

For any technical issues regarding the electronic transmission of this submission, please contact Hyung-Jin Kim at +1 (929) 505-2333 or via email at hkim@axsome.com.